Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Although other methods (e.g., autologous fat transfer, dermal-/collagen-based fillers) for
soft tissue reconstruction exist, each has distinct disadvantages leaving room for
improvement in this treatment area. Investigators in the Elisseeff Laboratory (Johns Hopkins
University Department of Biomedical Engineering) have recently generated a novel
tissue-derived material to create instructive matrices for soft tissue reconstruction called
Acellular Adipose Tissue (AAT). This material takes advantage of the inherent bioactivity and
unique mechanical properties of subcutaneous adipose tissue. Investigators' preclinical data
suggest that AAT is safe for use in small and large animals; investigators' clinical (Phase
I) data suggest that AAT is safe for use in humans. These data indicate that a Phase II,
dose-escalation study of AAT's safety and efficacy in human subjects is warranted.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Armed Forces Institute of Regenerative Medicine U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command